1. Home
  2. IVDA vs CVKD Comparison

IVDA vs CVKD Comparison

Compare IVDA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iveda Solutions Inc.

IVDA

Iveda Solutions Inc.

HOLD

Current Price

$0.34

Market Cap

2.9M

Sector

Technology

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$3.60

Market Cap

10.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IVDA
CVKD
Founded
2003
2022
Country
United States
United States
Employees
32
N/A
Industry
Computer Software: Prepackaged Software
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9M
10.3M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
IVDA
CVKD
Price
$0.34
$3.60
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
14.4M
73.1K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$2.55
52 Week High
$2.58
$14.64

Technical Indicators

Market Signals
Indicator
IVDA
CVKD
Relative Strength Index (RSI) 48.29 46.91
Support Level $0.25 $2.55
Resistance Level $0.42 $5.99
Average True Range (ATR) 0.07 0.55
MACD -0.01 0.08
Stochastic Oscillator 17.24 62.13

Price Performance

Historical Comparison
IVDA
CVKD

About IVDA Iveda Solutions Inc.

Iveda Solutions Inc offers smart city technologies globally, offering advanced AI-driven video surveillance solutions and a robust suite of Internet of Things (IoT) platforms that power digital transformation for cities and commercial clients worldwide. The smart cities market, as well as the AI and IoT segments, are poised for significant growth in the coming years. The company offers AI-intelligent video search, smart utility, smart sensors, gateways, and trackers, and IoT platforms (Products).

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: